Moderna Submits Updated COVID-19 Jab to FDA for Review - ALX Oncology Holdings (NASDAQ:ALXO), Moderna (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ: MRNA) announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1, the latest variant of the novel virus responsible for the 2020 pandemic.

Related Keywords

United States , ,Oncology Holdings ,World Health Organization ,Pfizer ,Moderna Inc ,European Medicines Agency Emergency Task ,Products Advisory Committee ,Related Biological Products Advisory Committee ,European Medicines Agency ,Emergency Task ,Zacks Rank ,Zacks Consensus Estimate ,